AN2 Therapeutics (ANTX) Other Operating Expenses (2021 - 2022)

AN2 Therapeutics' (ANTX) quarterly Other Operating Expenses came in at $1.0 million in Q3 2022, up 100.0% on a QoQ basis from $500000.0 in Q4 2021.

AN2 Therapeutics (ANTX) Other Operating Expenses (2021 - 2022) Analysis & Trends

AN2 Therapeutics (ANTX) has 2 years of Other Operating Expenses data on file, last reported at $1.0 million in Q3 2022.

On a quarterly basis, Other Operating Expenses changed N/A year-over-year to $1.0 million in Q3 2022; TTM through Jun 2023 was $1.0 million, a 100.0% increase from a year earlier, with the FY2022 full-year figure at $1.0 million, up 33.33% from the prior year.
Other Operating Expenses for Q3 2022 stood at $1.0 million, up from $500000.0 in the prior quarter.
Over the last five years, Other Operating Expenses for ANTX reached as high as $1.0 million in Q3 2022 and fell as low as $250000.0 in Q2 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	AN2 Therapeutics	167.57 Mn	167.57 Mn	-

Download Data